NCT00457561

Brief Summary

Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 5, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 6, 2007

Completed
Last Updated

April 6, 2007

Status Verified

April 1, 2007

First QC Date

April 5, 2007

Last Update Submit

April 5, 2007

Conditions

Hemodialysis

Keywords

The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in the Shizuoka prefecture area, and who survived for more than 3 months after the start of hemodialysis.

You may not qualify if:

  • Nothing particular.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Naro Ohashi, MD,PhD

    First Department of Medicine, Hamamatsu University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 5, 2007

First Posted

April 6, 2007

Last Updated

April 6, 2007

Record last verified: 2007-04